SYRS vs. CUE, PGNX, YMAB, AVTE, SIGA, FULC, TRDA, ALT, PEPG, and CYRX
Should you be buying Syros Pharmaceuticals stock or one of its competitors? The main competitors of Syros Pharmaceuticals include Cue Biopharma (CUE), Progenics Pharmaceuticals (PGNX), Y-mAbs Therapeutics (YMAB), Aerovate Therapeutics (AVTE), SIGA Technologies (SIGA), Fulcrum Therapeutics (FULC), Entrada Therapeutics (TRDA), Altimmune (ALT), PepGen (PEPG), and Cryoport (CYRX).
Cue Biopharma (NASDAQ:CUE) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, community ranking, valuation, dividends, analyst recommendations, media sentiment, earnings and profitability.
Cue Biopharma currently has a consensus price target of $8.00, suggesting a potential upside of 440.54%. Syros Pharmaceuticals has a consensus price target of $14.00, suggesting a potential upside of 171.84%. Given Syros Pharmaceuticals' higher possible upside, research analysts plainly believe Cue Biopharma is more favorable than Syros Pharmaceuticals.
In the previous week, Syros Pharmaceuticals had 1 more articles in the media than Cue Biopharma. MarketBeat recorded 1 mentions for Syros Pharmaceuticals and 0 mentions for Cue Biopharma. Syros Pharmaceuticals' average media sentiment score of 1.88 beat Cue Biopharma's score of 1.67 indicating that Cue Biopharma is being referred to more favorably in the media.
35.0% of Cue Biopharma shares are owned by institutional investors. Comparatively, 91.5% of Syros Pharmaceuticals shares are owned by institutional investors. 7.5% of Cue Biopharma shares are owned by company insiders. Comparatively, 12.3% of Syros Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Cue Biopharma has a beta of 1.99, indicating that its share price is 99% more volatile than the S&P 500. Comparatively, Syros Pharmaceuticals has a beta of 1.7, indicating that its share price is 70% more volatile than the S&P 500.
Syros Pharmaceuticals received 218 more outperform votes than Cue Biopharma when rated by MarketBeat users. Likewise, 63.89% of users gave Syros Pharmaceuticals an outperform vote while only 51.81% of users gave Cue Biopharma an outperform vote.
Cue Biopharma has higher earnings, but lower revenue than Syros Pharmaceuticals. Cue Biopharma is trading at a lower price-to-earnings ratio than Syros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Cue Biopharma has a net margin of -711.84% compared to Cue Biopharma's net margin of -1,656.34%. Syros Pharmaceuticals' return on equity of -128.30% beat Cue Biopharma's return on equity.
Summary
Cue Biopharma beats Syros Pharmaceuticals on 9 of the 17 factors compared between the two stocks.
Get Syros Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for SYRS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SYRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Syros Pharmaceuticals Competitors List
Related Companies and Tools
